🔗 Share this article

Given that the US undertakes unprecedented revisions to its immunization recommendations, one figure appears unexpectedly: Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 shots throughout the global health crisis and has concentrated on potential fatalities after Covid immunization in her brief time at the Food and Drug Administration.

Proposed Shifts to Childhood Immunization Schedule

Health officials planned to announce major changes to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US out of alignment with much of the international standard with no evidence for improved outcomes. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to head the division this year.

A New Direction at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has frequently advocated for discontinuing specific childhood immunization guidelines in the US in order to be more in line with Denmark's approach, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

So far comments, she has continued to focus on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Expertise

Høeg has no obvious experience in medication creation, oversight or management, which has been typical for previous directors of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for overseeing the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in leading a sizeable institution. She is not an expert in industry regulation.”

Previous commissioners of CBER would “grasp legal statutes and the research of medication creation”, said Janet Woodcock. “Frankly, she has not acquired the kind of background that prior appointees who headed CBER have had.”

The drug center has an vast range of responsibilities at the agency, the former commissioner stated.

“Everybody just zeroes in on the new drug program, but the generic drug division approves numerous generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and all of those have to be managed,” Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative element to the role, which supervises over 5,000 staff members. “It is a enormous management job, if you perform it correctly,” she said.

Agency Reaction and Disputed Policies

Regarding inquiries about Høeg’s qualifications and whether this appointment signifies greater collaboration among agency officials on vaccines, a representative responded that the “inquiries stem from incorrect presumptions”.

“This background is consistent with the duties of her role,” the official explained, noting the time Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the agency head's controversial expedited review system, a contentious one-day medication authorization process that allegedly worried her preceding directors. “How are these medications being chosen for this voucher program? Who makes the decisions?” Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards laxer regulations of pharmaceuticals, except for vaccines.”

Established Past Work on Vaccines

With immunizations, Høeg has a more established, if troubling, past, critics have noted. She released a study using unverified volunteer-provided data to assess the incidence of heart inflammation following Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming government encompassed revising rules for new vaccines and halting “optional” vaccines, she stated after the election on a podcast. At the FDA, Høeg has according to sources proposed barring teenage boys from getting Covid vaccinations.

“She’s an complete ideologue who begins with her beliefs and works backwards to retrofit the data in a highly disingenuous, untruthful fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other dissenters, {like|